Skip to main content

Table 8 Questionnaire-based outcomes in the pooled anxiety trial

From: Collaborative care for depression and anxiety disorders: results and lessons learned from the Danish cluster-randomized Collabri trials

 

6-months’ follow-up

 

15-months’ follow-up

CC (n = 369)

TAU (n = 37)

P

Effect size

CC (n = 369)

TAU (n = 37)

P

Primary outcome

 BAI

11.5 (10.6–12.4)

14.6 (9.9–19.3)

0.206

0.33

11.0 (10.2–11.9)

12.7 (10.2–15.3)

0.209

Secondary outcomes

 BDI-II

9.2 (8.3–10.1)

11.3 (6.3–16.3)

0.418

 

9.1 (8.3–9.9)

10.9 (7.7–14.0)

0.295

 SCL-90-Ra

48.6 (43.8–53.3)

64.9 (40.5–89.4)

0.200

 

47.4 (42.6–52.0)

42.7 (23.1–62.2)

0.657

 GAF

72.5 (70.9–74.1)

72.9 (68.8–77.0)

0.855

 

74.8 (73.3–76.3)

80.3 (71.6–89.0)

0.224

Explorative outcomes

 The Diagnostic Apathia Scale

2.5 (2.2–2.8)

2.4 (1.3–3.5)

0.843

 

2.1 (1.9–2.4)

2.1 (1.0–3.3)

0.961

 PSP

72.6 (71.2–74.1)

72.7 (69.3–76.2)

0.951

 

75.3 (73.7–76.9)

82.1 (65.5–98.8)

0.417

 SDS

6.2 (5.4–7.0)

7.1 (4.6–9.7)

0.485

 

5.5 (4.6–6.3)

7.1 (4.5–9.7)

0.243

 WHO-5

59.1 (56.7–61.4)

59.2 (48.9–69.3)

0.995

 

61.7 (59.0–64.5)

53.0 (37.8–68.2)

0.271

 Personal Controlb

23.3 (22.8–23.8)

22.2 (20.2–24.2)

0.282

 

19.9 (19.6–20.2)

20.3 (19.3–21.2)

0.465

 Control/Manage Depressionc

7.1 (6.9–7.3)

6.0 (4.9–7.0)

0.031

 

7.2 (6.9–7.4)

7.1 (6.3–7.9)

0.885

 Obtain Help from Community, Family, Friendsc

7.2 (6.9–7.4)

6.9 (5.8–8.0)

0.637

 

7.4 (7.2–7.6)

7.3 (6.6–8.1)

0.848

 EQ-5D-3 L

0.84 (0.82–0.86)

0.78 (0.67–0.90)

0.294

 

0.8 (0.8–0.9)

0.9 (0.8–0.9)

0.536

 PRISEd

15.0 (13.0–16.9)

14.0 (5.3–22.7)

0.828

 

12.1 (9.9–14.3)

15.4 (0.8–30.6)

0.662

 Remission, %

45.7 (40.1–51.2)

39.2 (22.3–56.2)

0.481

 

49.0 (43.2–54.9)

42.3 (24.6–60.0)

0.442

 INSPIRE-S

74.0 (70.7–77.3)

67.7 (50.0–85.4)

0.488

 

–

–

 

 INSPIRE-R

85.8 (83.6–88.0)

82.4 (69.7–95.1)

0.604

 

–

–

 

 CSQ-8

26.7 (26.2–27.4)

23.9 (17.5–30.2)

0.368

 

–

–

 
  1. Abbreviations: BDI-II Beck Depression Inventory II, BAI Beck Anxiety Inventory, CC Collaborative care, CSQ-8 Client Satisfaction Questionnaire, EQ-5D-3L EuroQol Five Dimensions Questionnaire with Three Levels, GAF-F Global Assessment of Functioning, INSPIRE-S Recovery support from staff (Support), INSPIRE-R Recovery support from staff (Relationship), PRISE Patient Rated Inventory of Side Effects, PSP Personal and Social Performance Scale, SCL-90-R Symptom Checklist-90-Revised, SDS Sheehan Disability Scale, TAU Treatment-as-usual, WHO-5 World Health Organization-5 Well-Being Index
  2. Note: Means are estimated based on imputed data. In BDI-II, BAI, SCL-90-R, SDS, The Diagnostic Apathia Scale, and PRISE, lower scores are associated with a better outcome. In GAF, PSP, WHO-5, Personal control subscale from IPQ-R, Control/manage Depression subscale. Obtain Help from Community, Family, Friends subscale, EQ-5D-3L, CSQ-8, INSPIRE-S, and INSPIRE-R higher scores are associated with a better outcome
  3. a SCL-90-R was modified slightly as a reference period of two weeks was used instead of one week. b Subscale from the Illness Perception Questionnaire-Revised (IPQ-R). c Subscale from the Chronic Disease Self-Efficacy Scales. d Side effects were reported for the proportion of participants who used medication